CrestaRx

OUR WORK

CrestaRx is an early-stage biotechnology company advancing a new class of targeted therapies for solid tumours. At the heart of its approach is a commitment to molecular precision: engineering small molecules that intervene in well-characterised cancer pathways while avoiding unnecessary toxicity. By focusing on selectivity from the earliest stages of drug design, CrestaRx aims to bring forward treatments that are not only effective, but also better tolerated by patients.

​

Still in the clinical development phase, CrestaRx needed a brand identity that could carry scientific depth while signalling ambition and future readiness. Onevizyn partnered closely with the founding team to clarify the narrative and visualise the opportunity. We helped reshape the investor story, distilling complex science into accessible, confident language that resonates with both scientific and financial audiences.

​